Positherapy: Targeted nuclear therapy of breast cancer with 18F-2-deoxy-2-fluoro-D-glucose

Renee M. Moadel, Richard H. Weldon, Ellen B. Katz, Ping Lu, Joseph Mani, Mark Stahl, M. Donald Blaufox, Richard G. Pestell, Maureen J. Charron, Ekaterina Dadachova

Research output: Contribution to journalArticle

38 Citations (Scopus)

Abstract

Breast cancer remains a major cause of cancer death in women in the United States. Novel therapies are needed for patients when standard treatments are ineffective. We have recently shown on a cellular level the therapeutic potential of positrons in malignancy. Here, we report for the first time positron. therapy with 18F-2-deoxy-2-fluoro-D-glucose ( 18F-FDG) in a breast cancer animal model to affect tumor growth rate and survival (positherapy). We used xenografted mammary tumors in nude mice using Notch mammary cancer cells which also express ras oncogene. Notch xenografted tumors actively took up 18F-FDG with a tumor to normal tissue ratio of 3.24. Tumor-bearing mice were treated with 2.5 mCi 18F-FDG, which is equivalent to the physiological human maximum tolerated dose. Positherapy resulted in both significant prolongation of survival and decrease in tumor growth rate in comparison with nontreated controls. Immunoblot of Notch tumors showed the presence of glucose transporters (GLUT) 1, 4, and 8. Substantial differences between GLUT1, GLUT4, and GLUT8 were observed in their distribution within the tumor mass. Whereas GLUT4 and GLUT8 were distributed relatively homogeneously throughout the tumor, GLUT1 was confined to necrotic areas. Immunofluorescence double labeling was used to determine cellular localization of GLUTs. GLUT1 was expressed mostly at the cell membrane. GLUT4 and GLUT8 were mostly localized to cytoplasmic compartments with some GLUT4 expressed at or near the cell membrane in close proximity to GLUT1. Thus, GLUT1 was likely responsible for the 18F-FDG uptake by tumor cells with some possible contribution from GLUT4. These results are important for the development of positherapy with 18F-FDG for refractory metastatic breast and other cancers.

Original languageEnglish (US)
Pages (from-to)698-702
Number of pages5
JournalCancer Research
Volume65
Issue number3
StatePublished - Feb 1 2005

Fingerprint

Fluorodeoxyglucose F18
Breast Neoplasms
Neoplasms
Therapeutics
Cell Membrane
Electrons
ras Genes
Maximum Tolerated Dose
Facilitative Glucose Transport Proteins
Growth
Nude Mice
Fluorescent Antibody Technique
Cause of Death
Survival Rate
Animal Models

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Moadel, R. M., Weldon, R. H., Katz, E. B., Lu, P., Mani, J., Stahl, M., ... Dadachova, E. (2005). Positherapy: Targeted nuclear therapy of breast cancer with 18F-2-deoxy-2-fluoro-D-glucose. Cancer Research, 65(3), 698-702.

Positherapy : Targeted nuclear therapy of breast cancer with 18F-2-deoxy-2-fluoro-D-glucose. / Moadel, Renee M.; Weldon, Richard H.; Katz, Ellen B.; Lu, Ping; Mani, Joseph; Stahl, Mark; Blaufox, M. Donald; Pestell, Richard G.; Charron, Maureen J.; Dadachova, Ekaterina.

In: Cancer Research, Vol. 65, No. 3, 01.02.2005, p. 698-702.

Research output: Contribution to journalArticle

Moadel, RM, Weldon, RH, Katz, EB, Lu, P, Mani, J, Stahl, M, Blaufox, MD, Pestell, RG, Charron, MJ & Dadachova, E 2005, 'Positherapy: Targeted nuclear therapy of breast cancer with 18F-2-deoxy-2-fluoro-D-glucose', Cancer Research, vol. 65, no. 3, pp. 698-702.
Moadel RM, Weldon RH, Katz EB, Lu P, Mani J, Stahl M et al. Positherapy: Targeted nuclear therapy of breast cancer with 18F-2-deoxy-2-fluoro-D-glucose. Cancer Research. 2005 Feb 1;65(3):698-702.
Moadel, Renee M. ; Weldon, Richard H. ; Katz, Ellen B. ; Lu, Ping ; Mani, Joseph ; Stahl, Mark ; Blaufox, M. Donald ; Pestell, Richard G. ; Charron, Maureen J. ; Dadachova, Ekaterina. / Positherapy : Targeted nuclear therapy of breast cancer with 18F-2-deoxy-2-fluoro-D-glucose. In: Cancer Research. 2005 ; Vol. 65, No. 3. pp. 698-702.
@article{ed38d6ab56c64e069eb639053ad242cb,
title = "Positherapy: Targeted nuclear therapy of breast cancer with 18F-2-deoxy-2-fluoro-D-glucose",
abstract = "Breast cancer remains a major cause of cancer death in women in the United States. Novel therapies are needed for patients when standard treatments are ineffective. We have recently shown on a cellular level the therapeutic potential of positrons in malignancy. Here, we report for the first time positron. therapy with 18F-2-deoxy-2-fluoro-D-glucose ( 18F-FDG) in a breast cancer animal model to affect tumor growth rate and survival (positherapy). We used xenografted mammary tumors in nude mice using Notch mammary cancer cells which also express ras oncogene. Notch xenografted tumors actively took up 18F-FDG with a tumor to normal tissue ratio of 3.24. Tumor-bearing mice were treated with 2.5 mCi 18F-FDG, which is equivalent to the physiological human maximum tolerated dose. Positherapy resulted in both significant prolongation of survival and decrease in tumor growth rate in comparison with nontreated controls. Immunoblot of Notch tumors showed the presence of glucose transporters (GLUT) 1, 4, and 8. Substantial differences between GLUT1, GLUT4, and GLUT8 were observed in their distribution within the tumor mass. Whereas GLUT4 and GLUT8 were distributed relatively homogeneously throughout the tumor, GLUT1 was confined to necrotic areas. Immunofluorescence double labeling was used to determine cellular localization of GLUTs. GLUT1 was expressed mostly at the cell membrane. GLUT4 and GLUT8 were mostly localized to cytoplasmic compartments with some GLUT4 expressed at or near the cell membrane in close proximity to GLUT1. Thus, GLUT1 was likely responsible for the 18F-FDG uptake by tumor cells with some possible contribution from GLUT4. These results are important for the development of positherapy with 18F-FDG for refractory metastatic breast and other cancers.",
author = "Moadel, {Renee M.} and Weldon, {Richard H.} and Katz, {Ellen B.} and Ping Lu and Joseph Mani and Mark Stahl and Blaufox, {M. Donald} and Pestell, {Richard G.} and Charron, {Maureen J.} and Ekaterina Dadachova",
year = "2005",
month = "2",
day = "1",
language = "English (US)",
volume = "65",
pages = "698--702",
journal = "Cancer Research",
issn = "0008-5472",
publisher = "American Association for Cancer Research Inc.",
number = "3",

}

TY - JOUR

T1 - Positherapy

T2 - Targeted nuclear therapy of breast cancer with 18F-2-deoxy-2-fluoro-D-glucose

AU - Moadel, Renee M.

AU - Weldon, Richard H.

AU - Katz, Ellen B.

AU - Lu, Ping

AU - Mani, Joseph

AU - Stahl, Mark

AU - Blaufox, M. Donald

AU - Pestell, Richard G.

AU - Charron, Maureen J.

AU - Dadachova, Ekaterina

PY - 2005/2/1

Y1 - 2005/2/1

N2 - Breast cancer remains a major cause of cancer death in women in the United States. Novel therapies are needed for patients when standard treatments are ineffective. We have recently shown on a cellular level the therapeutic potential of positrons in malignancy. Here, we report for the first time positron. therapy with 18F-2-deoxy-2-fluoro-D-glucose ( 18F-FDG) in a breast cancer animal model to affect tumor growth rate and survival (positherapy). We used xenografted mammary tumors in nude mice using Notch mammary cancer cells which also express ras oncogene. Notch xenografted tumors actively took up 18F-FDG with a tumor to normal tissue ratio of 3.24. Tumor-bearing mice were treated with 2.5 mCi 18F-FDG, which is equivalent to the physiological human maximum tolerated dose. Positherapy resulted in both significant prolongation of survival and decrease in tumor growth rate in comparison with nontreated controls. Immunoblot of Notch tumors showed the presence of glucose transporters (GLUT) 1, 4, and 8. Substantial differences between GLUT1, GLUT4, and GLUT8 were observed in their distribution within the tumor mass. Whereas GLUT4 and GLUT8 were distributed relatively homogeneously throughout the tumor, GLUT1 was confined to necrotic areas. Immunofluorescence double labeling was used to determine cellular localization of GLUTs. GLUT1 was expressed mostly at the cell membrane. GLUT4 and GLUT8 were mostly localized to cytoplasmic compartments with some GLUT4 expressed at or near the cell membrane in close proximity to GLUT1. Thus, GLUT1 was likely responsible for the 18F-FDG uptake by tumor cells with some possible contribution from GLUT4. These results are important for the development of positherapy with 18F-FDG for refractory metastatic breast and other cancers.

AB - Breast cancer remains a major cause of cancer death in women in the United States. Novel therapies are needed for patients when standard treatments are ineffective. We have recently shown on a cellular level the therapeutic potential of positrons in malignancy. Here, we report for the first time positron. therapy with 18F-2-deoxy-2-fluoro-D-glucose ( 18F-FDG) in a breast cancer animal model to affect tumor growth rate and survival (positherapy). We used xenografted mammary tumors in nude mice using Notch mammary cancer cells which also express ras oncogene. Notch xenografted tumors actively took up 18F-FDG with a tumor to normal tissue ratio of 3.24. Tumor-bearing mice were treated with 2.5 mCi 18F-FDG, which is equivalent to the physiological human maximum tolerated dose. Positherapy resulted in both significant prolongation of survival and decrease in tumor growth rate in comparison with nontreated controls. Immunoblot of Notch tumors showed the presence of glucose transporters (GLUT) 1, 4, and 8. Substantial differences between GLUT1, GLUT4, and GLUT8 were observed in their distribution within the tumor mass. Whereas GLUT4 and GLUT8 were distributed relatively homogeneously throughout the tumor, GLUT1 was confined to necrotic areas. Immunofluorescence double labeling was used to determine cellular localization of GLUTs. GLUT1 was expressed mostly at the cell membrane. GLUT4 and GLUT8 were mostly localized to cytoplasmic compartments with some GLUT4 expressed at or near the cell membrane in close proximity to GLUT1. Thus, GLUT1 was likely responsible for the 18F-FDG uptake by tumor cells with some possible contribution from GLUT4. These results are important for the development of positherapy with 18F-FDG for refractory metastatic breast and other cancers.

UR - http://www.scopus.com/inward/record.url?scp=13444263251&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=13444263251&partnerID=8YFLogxK

M3 - Article

C2 - 15705862

AN - SCOPUS:13444263251

VL - 65

SP - 698

EP - 702

JO - Cancer Research

JF - Cancer Research

SN - 0008-5472

IS - 3

ER -